Stockscreener 앱 받기
5.69
11.13%
0.57
시장 영업 전:
5.79
0.10
+1.76%
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Protara Therapeutics (TARA) Begins Phase 3 THRIVE-3 Trial for Ke - GuruFocus
TARA Stock Initiated with 'Overweight' Rating by Piper Sandler | - GuruFocus
Protara begins patient dosing in phase 3 trial for IV choline therapy - Investing.com India
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support - The Manila Times
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Trial tests first IV choline therapy for patients on long-term IV nutrition - Stock Titan
Why analysts recommend Protara Therapeutics Inc. (1KPA) stock2026 world cup usa national team semifinals young talents counter attacking expert forecast statistical analysis - ulpravda.ru
Why Protara Therapeutics Inc. stock could outperform in 20252026 world cup usa national team quarterfinals young talents high defensive line tactical prediction insights - ulpravda.ru
Protara, Ceribell rise on FDA breakthrough designations - MSN
FDA grants breakthrough therapy designation to Protara’s LM treatment By Investing.com - Investing.com Nigeria
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
Movement Recap: How strong is Protara Therapeutics Inc stock revenue growthJuly 2025 PostEarnings & Long-Term Capital Growth Strategies - moha.gov.vn
Protara Therapeutics updates on TARA-002 development - The Pharma Letter
Protara, CeriBell rise on FDA breakthrough designations (TARA:NASDAQ) - Seeking Alpha
Protara Therapeutics (TARA) Gains FDA Designations for TARA-002 - GuruFocus
FDA grants breakthrough therapy designation to Protara’s LM treatment - Investing.com
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations - The Manila Times
Protara Therapeutics Receives Both FDA Breakthrough Therapy - GlobeNewswire
Protara Therapeutics’ TARA-002 Study: A Potential Game-Changer for Lymphatic Malformations - MSN
Levels Update: How forex fluctuations impact Protara Therapeutics Inc 1KPA stock2025 Historical Comparison & Fast Entry and Exit Trade Plans - moha.gov.vn
Assenagon Asset Management S.A. Invests $1.34 Million in Protara Therapeutics, Inc. $TARA - Defense World
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 - Sahm
Sentiment Watch: Can Protara Therapeutics Inc stock attract ESG capital inflows2025 EndofYear Setup & Weekly High Potential Stock Alerts - moha.gov.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Resistance Check: Is Protara Therapeutics Inc. (1KPA) stock attractive for dividend growth2025 Technical Patterns & Fast Entry Momentum Trade Alerts - moha.gov.vn
Can Protara Therapeutics Inc. stock attract ESG capital inflowsPrice Action & Daily Chart Pattern Signal Reports - DonanımHaber
Protara Therapeutics raises $86.3 million in offering - MSN
Protara Therapeutics Raises $86.3 Million in Offering - TipRanks
Protara Therapeutics, Inc. (NASDAQ: TARA) details $86.3M equity raise from stock sale - Stock Titan
What analysts say about Protara Therapeutics Inc stockSwing Trading Ideas & Get Alerts Before Market Turns Ugly - earlytimes.in
Acorn Capital Advisors LLC Acquires 472,315 Shares of Protara Therapeutics, Inc. $TARA - MarketBeat
Protara Therapeutics, Inc. $TARA is Velan Capital Investment Management LP's 4th Largest Position - MarketBeat
Protara Therapeutics completes $75 million stock offering - MSN
Protara Announces Closing of $75 Million Public Offering - The Manila Times
Protara announces proposed public offering - MSN
Protara Therapeutics Completes $75 Million Stock Offering - TipRanks
Protara therapeutics raises $75 million in public offering - Investing.com
Protara Therapeutics Closes $75 Million Public Offering - marketscreener.com
Protara therapeutics raises $75 million in public offering By Investing.com - Investing.com India
Protara Therapeutics (Nasdaq: TARA) closes $75M stock sale of 13.0M shares at $5.75 - Stock Titan
HC Wainwright & Co. reiterates Protara Therapeutics (TARA) buy recommendation - MSN
Is Protara Therapeutics Inc a good long term investmentOptions Trading Strategies & High Return Trading Strategies - earlytimes.in
Protara Therapeutics Inc. (TARA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Protara Therapeutics: Stock Offer Takes the Spotlight - StocksToTrade
Protara Therapeutics (TARA) Stock Plunges After $75 Million Offering: Latest Trial Data, Analyst Targets and Outlook as of December 5, 2025 - ts2.tech
Protara Prices $75 Mln Offering To Advance TARA-002 And Broader Pipeline - Nasdaq
Biotech co Protara slides on $75 mln share sale - TradingView — Track All Markets
Protara Therapeutics Shares Sink 16% After $75 Mln Public Offering - Nasdaq
Protara Therapeutics (Nasdaq: TARA) prices 13,043,479-share, $75M public deal - Stock Titan
Protara Therapeutics (TARA) Launches $75M Public Offering - GuruFocus
Protara Therapeutics Prices $75 Million Share Offering - marketscreener.com
28.63%
자본화:
|
볼륨(24시간):